New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
14:19 EDTCTRX, CICatamaran weakness a buying opportunity, says Cowen
Cowen attributes the weakness in shares of Catamaran (CTRX) to concerns over the company's relationship with Cigna (CI) should Cigna decide to keep its PBM. Cowen always expected Cigna to keep its PBM, and thinks the market is incorrectly assuming that Cigna's relationship with Catamaran will dissolve if that were to be the case. Cowen thinks the market is misunderstanding the services that Catamaran currently provides to Cigna and recommends buying the stock on today's pullback.
News For CTRX;CI From The Last 14 Days
Check below for free stories on CTRX;CI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2014
11:31 EDTCIAetna rises after topping expectations, raising guidance
Shares of healthcare insurer Aetna (AET) are advancing after its first quarter results topped analysts' consensus estimates and it raised its fiscal 2014 outlook. WHAT'S NEW: This morning, Aetna reported Q1 adjusted earnings per share of $1.98 and revenue of $13.99B, topping expectations of $1.56 and $13.72B, respectively. Medical membership in Q1 increased to over 22.7M, a sequential increase of 529,000 members. Aetna is targeting year-end medical membership of more than 23M, an increase of 800,000-1M members for the year. “Aetna posted higher operating earnings, operating revenues and medical membership in the first quarter, each representing historic highs for our company...This performance is once again a testament to the strength of our diversified portfolio, continued progress in integrating the Coventry acquisition, pricing discipline and solid execution. Our strong membership growth in the quarter came from both our commercial and government businesses, and we project this momentum will continue,” said Mark Bertolini, Aetna chairman, CEO and president. WHAT'S NOTABLE: The company raised its FY14 EPS view to $6.35-$6.55 from at least $6.25, versus consensus of $6.38. It also raised its FY14 revenue outlook to $56B-$57B from at least $54B, compared to consensus of $54.89B. PRICE ACTION: In late morning trading, Aetna rose $3.61, or 5.2%, to $72.52 on heavy trading volume. Including today's advance, the stock up about 27% over the past twelve months. OTHERS TO WATCH: Other companies in the healthcare benefits space include UnitedHealth Group (UNH), Cigna (CI), WellPoint (WLP) and Humana (HUM), all of which are higher on the session.
April 15, 2014
10:00 EDTCTRXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:20 EDTCTRXCatamaran upgraded to Outperform from Perform at Oppenheimer
Subscribe for More Information
06:32 EDTCIPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 14, 2014
15:02 EDTCTRXCatamaran Mat volatility increases, shares near two-year low
Subscribe for More Information
11:09 EDTCTRXOptions with increasing implied volatility: HZNP VJET YOKU CTRX CBS
08:02 EDTCTRXCatamaran recent sell-off overdone, says Jefferies
Jefferies views the recent sell-off in shares of Catamaran as overdone. The firm attributes the move to concerns about the company's ability to meet Q1 consensus and win new contracts. Jefferies expects Catamaran shares to bounce back to the mid-$40s soon after the Q1 report and it keeps a Buy rating on the stock.
April 10, 2014
14:27 EDTCTRXCatamaran sell-off overdone, says UBS
Subscribe for More Information
09:23 EDTCTRXCatamaran channel checks cautious, says Cleveland Research
Cleveland Research said Catamaran checks indicate client frustration with customer service and implementation issues. The firm sees downside to 2014 estimates from higher expenses, system upgrades and potential to pay performance guarantees.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use